2018 年第 10 期 第 13 卷

丁苯酞在帕金森病伴认知障碍患者治疗中的临床效果观察

Clinical effect of butylphthalide on cognitive impairment in patients with Parkinson′s disease

作者：李晓利宋丽倩曹立波杨文月田磊胡素芬

英文作者：

单位：056000河北省邯郸市第一医院药学部

英文单位：

关键词：帕金森病；丁苯酞；认知功能；C反应蛋白；临床疗效

英文关键词：

• 摘要：

• 【摘要】目的    观察丁苯酞在帕金森病伴认知障碍患者治疗中的临床效果。方法    选取2016年 1月至2018年1月河北省邯郸市第一医院神经内科收治的帕金森病伴认知障碍患者80例，完全随机分为观察组和对照组，各40例。对照组在常规治疗基础上口服盐酸多奈哌齐；观察组在对照组基础上加服丁苯酞软胶囊，均治疗12周。观察2组临床疗效，比较2组患者在治疗前后帕金森病评定量表（UPDRS）、蒙特利尔认知评估量表（MoCA）、简易精神状态检查量表（MMSE）、日常生活活动能力量表（ADL）评分及血清C反应蛋白（CRP）、神经营养因子3（NT-3）、重组人帕金森病蛋白7（PARK7）水平的变化。结果    观察组总有效率高于对照组［92.5%（37/40）比70.0%（28/40）］，差异有统计学意义（P<0.05）。治疗后观察组UPDRS评分明显低于对照组［（25±4）分比（35±6）分］，MoCA、MMSE、ADL评分明显高于对照组［（28±5）分比（25±5）分、（28±5）分比（26±4）分、（79±12）分比（63±10）分］，差异均有统计学意义（均P<0.05）。治疗后观察组CRP和PARK7水平明显低于对照组，NT-3水平明显高于对照组［（3.9±0.5）mg/L比（6.5±0.8）mg/L、（18.6±2.7）μg/L比（26.4±3.6）μg/L、（35.2±6.5）μg/L比（23.9±5.8）μg/L］，差异均有统计学意义（均P<0.05）。结论    丁苯酞可显著改善帕金森病患者的认知功能。

• 【Abstract】Objective    To observe the clinical effect of butylphthalide on cognitive impairment in patients with Parkinson′s disease. Methods    From January 2016 to January 2018, 80 patients with Parkinson′s disease admitted to the First Hospital of Handan were randomly divided into observation group and control group, with 40 cases in each group. The control group took donepezil hydrochloride; the observation group took donepezil hydrochloride and butylphthalide; both groups were treated for 12 weeks. Unified Parkinson′s Disease Rating Scale(UPDRS), Montreal Cognitive Assessment Scale(MoCA), Mini-mental State Scale(MMSE), Activity of Daily Living Scale(ADL) and levels of C-reactive protein(CRP), neurotrophin-3(NT-3) and recombinant human Parkinson′s disease protein 7(PARK7) were analyzed. Results    The total effective rate in observation group was significantly higher than that in control group［92.5%（37/40） vs 70.0%（28/40）］（P<0.05）. After treatment, UPDRS score in observation group was significantly lower and scores of MoCA, MMSE and ADL were significantly higher than those in control group［（25±4） vs （35±6）, （28±5） vs （25±5）, （28±5） vs （26±4）, （79±12） vs （63±10）］(P<0.05). Levels of CRP and PARK7 in observation group were significantly lower and NT-3 was significantly higher than those in control group［（3.9±0.5）mg/L vs （6.5±0.8）mg/L, （18.6±2.7）μg/L vs （26.4±3.6）μg/L, （35.2±6.5）μg/L vs （23.9±5.8）μg/L］(P<0.05). Conclusion    Butylphthalide can significantly improve cognitive function in patients with Parkinson′s disease.